clofibric acid has been researched along with Stroke in 6 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Betaine is an osmolyte, supplies methyl groups, and controls plasma homocysteine." | 2.74 | Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. ( Chambers, ST; Elmslie, JL; Fink, JN; George, PM; Lever, M; Richards, AM; Scott, RS; Slow, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Elmslie, JL | 1 |
| Scott, RS | 1 |
| Richards, AM | 1 |
| Fink, JN | 1 |
| Chambers, ST | 1 |
| Robins, SJ | 1 |
| Caslake, MJ | 1 |
| Packard, CJ | 1 |
| Mullard, AJ | 1 |
| Reeves, MJ | 1 |
| Jacobs, BS | 1 |
| Kothari, RU | 1 |
| Birbeck, GL | 1 |
| Maddox, K | 1 |
| Stoeckle-Roberts, S | 1 |
| Wehner, S | 1 |
| Athyros, VG | 1 |
| Papageorgiou, AA | 1 |
| Kontopoulos, AG | 1 |
3 reviews available for clofibric acid and Stroke
| Article | Year |
|---|---|
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Topics: Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; | 2003 |
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Biomarkers; Clofibric Acid; Coronary Disease; Enzyme | 2005 |
2 trials available for clofibric acid and Stroke
| Article | Year |
|---|---|
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine.
Topics: Acute Coronary Syndrome; Aged; Betaine; Clofibric Acid; Cohort Studies; Diabetes Complications; Fema | 2009 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
1 other study available for clofibric acid and Stroke
| Article | Year |
|---|---|
Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry.
Topics: Aged; Anticoagulants; Cholestyramine Resin; Clofibric Acid; Female; Hospital Records; Hospitalizatio | 2006 |